Mississippi 340B Law Upheld by Appeals Court in Two Cases

Why It Matters

The ruling secures a critical revenue stream for safety‑net hospitals and signals that state‑level 340B protections can withstand industry challenges, potentially shaping nationwide policy.

Key Takeaways

• 5th Circuit affirms Mississippi's 340B contract‑pharmacy law.
• Novartis, PhRMA, and AbbVie lose injunction attempts.
• Law safeguards discounted drugs for safety‑net hospitals.
• AHA backs law with amicus brief, highlighting industry support.
• Ruling may influence other states' 340B policy decisions.

Pulse Analysis

The 340B Drug Pricing Program, created in 1992, allows eligible hospitals and clinics to purchase outpatient medicines at steep discounts, stretching scarce resources for underserved patients. Contract‑pharmacy arrangements—where hospitals extend their 340B eligibility to outside pharmacies—have become a focal point of industry debate, as manufacturers argue they dilute discount benefits. Mississippi enacted a law in 2023 mandating that drug makers honor 340B pricing for any pharmacy contracted with a covered entity, prompting lawsuits from major pharma groups seeking to block enforcement.

The Fifth Circuit’s affirmation of the lower‑court rulings marks a decisive victory for the state and the broader safety‑net hospital community. By rejecting injunctions from Novartis, PhRMA, and AbbVie, the court reinforced the legal footing of state‑level 340B protections, ensuring hospitals can continue to leverage contract pharmacies without losing discount eligibility. For manufacturers, the decision curtails a strategy that could have limited discount exposure, while preserving a predictable regulatory environment. Hospitals, in turn, retain a vital source of margin that supports uncompensated care and community health initiatives.

Beyond Mississippi, the decision sends a clear signal to other jurisdictions contemplating similar statutes. States such as Texas and Ohio, which have faced comparable legal pressure, may view the ruling as precedent for defending their own 340B frameworks. The outcome also underscores the growing influence of hospital industry groups, exemplified by the American Hospital Association’s amicus brief, in shaping policy outcomes. As litigation continues, stakeholders will watch for potential Supreme Court involvement, but for now the appellate ruling bolsters the momentum of state‑driven 340B reforms across the nation.